halofuginone has been researched along with paclitaxel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fang, K; Gao, X; Guo, D; Hu, S; Ji, C; Ji, H; Jiang, S; Li, G; Peng, L; Si, H; Song, X; Wang, J; Zhang, J; Zuo, R | 1 |
2 other study(ies) available for halofuginone and paclitaxel
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compounding; Female; Humans; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Micelles; Paclitaxel; Piperidines; Polymers; Quinazolinones; Reactive Oxygen Species; Treatment Outcome; Triple Negative Breast Neoplasms; Vitamin E | 2021 |